R. Mehta
Managing Director
Founded RIVANOVA in 2005 after fourteen years in formulation development. Retains direct oversight of quality policy and chairs the quarterly product-quality review.
Leadership
Experience that
compounds
A leadership bench with a combined 180+ years across formulation science, regulatory affairs, quality systems and global commercial operations.
Executive leadership
The people who sign the release
In pharmaceutical manufacturing, accountability has names attached. These are the people whose signatures appear on batch releases, regulatory filings and audit responses.
S. Desai
Executive Director — Operations
Runs all four production blocks and the engineering function. Led the commissioning of the aseptic injectable suite and the fourth compression line.
Dr. A. Nambiar
Head — Quality Assurance
Holds independent release authority reporting directly to the board, not to production. Owns deviation, CAPA and change-control governance across the site.
Dr. P. Varma
Head — Research & Development
Leads 42 scientists across formulation, analytical development and packaging science. Specialises in bioavailability enhancement for poorly soluble molecules.
K. Joshi
Head — Regulatory Affairs
Responsible for 180+ live product registrations across 25 countries, CTD and ACTD dossier preparation, and all interactions with regulatory authorities.
M. Iyer
Head — Sales & Marketing
Oversees the domestic field force, distributor network and institutional business. Built the territory-protection framework that governs franchise appointments.
T. Ghosh
Head — International Business
Manages export partnerships, local agent relationships and contract manufacturing across South-East Asia, Africa, the CIS and Latin America.
N. Bhatt
Chief Financial Officer
Leads finance, procurement and investor relations. Responsible for the capital plan behind the last three capacity expansions.
Governance
Structured so quality cannot be overruled
The most consequential decision in our organisation chart is a reporting line: quality assurance does not report to the people whose targets it can block. Everything else follows from that.
Independent release authority
The QA head reports to the board directly. No production or commercial manager can override a rejection, and no batch ships without a QA signature.
Quarterly product quality review
Every product line is reviewed for trends in deviations, complaints, out-of-specification results and stability data, chaired by the Managing Director.
Protected disclosure
Any employee can escalate a quality or safety concern directly to QA or the board without going through their line manager, and without consequence.
Annual self-inspection
A cross-functional team audits every department against GMP requirements each year, with findings tracked to closure like any regulatory observation.
The first time our QA head rejected a batch worth more than that month's profit, nobody called a meeting about it. That is the culture we were trying to build.
R. Mehta
Managing Director
0
Combined years of leadership experience in pharmaceutical manufacturing.
0
Regulatory and customer audits hosted in the last three years.
Speak to the leadership
Partnership, audit and investor enquiries reach the relevant director directly, not a general inbox.
Join the team
We hire for rigour and curiosity across production, quality, research and commercial functions.